HPV vaccine program renewed

News
Article

A program with the goal of expanding human papillomavirus (HPV) vaccination and preventing HPV-related cancers has been expanded.

Eliminating the public health threat of cancers linked to human papillomavirus (HPV) has been a key program of the American Cancer Society. The organization decided to renew their program Mission: HPV Cancer Free with the hope that it could keep HPV vaccination levels on track.

The program’s goal is to reach a vaccination rate of 80% of adolescents aged 13 years receiving it by 2026. A recent report found a 71% drop in the number of health care visits involving patients aged 7 to 17 years.

Roughly 14 million people in the United States are infect by HPV every year and overall 8 in 10 people will be infected with HPV at some point in their lifetime. The vaccine performs best when administered to children aged 9 to 12 years. In fact, 2 doses of the vaccine administered at this point of life can prevent more than 90% of HPV-related cancers.

For more on the renewal, check out our sister publication Contemporary Clinic.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jillian Cotter, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.